| Benign | Low suspicion | Intermediate suspicion | High suspicion | ||||
---|---|---|---|---|---|---|---|---|
RF | SRF<lc(0.265) | lc≤SRF<0.5 | 0.5≤SRF<hc(0.784) | SRF≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 16 | 0 | 12 | 2 | 13 | 18 | 9 | 220 |
 | 100% | 0% | 75.7% | 14.3% | 41.9% | 58.1% | 3.9% | 96.1% |
LR | SLR<lc(0.267) | lc≤SLR<0.5 | 0.5≤SLR<hc(0.838) | SLR≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 23 | 1 | 10 | 6 | 10 | 17 | 7 | 216 |
 | 95.8% | 4.2% | 62.5% | 37.5% | 37.0% | 63.0% | 3.1% | 96.9% |
SVM | SSVM<lc(0.277) | lc≤SSVM<0.5 | 0.5≤SSVM<hc(0.850) | SSVM≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 23 | 4 | 5 | 3 | 15 | 21 | 7 | 212 |
 | 85.2% | 14.8% | 62.5% | 37.5% | 41.7% | 58.3% | 3.2% | 96.8% |
NET | SNET<lc(0.300) | lc≤SNET<0.5 | 0.5≤SNN<hc(0.820) | SNET≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 26 | 1 | 11 | 6 | 7 | 16 | 7 | 217 |
 | 96.3% | 3.7% | 64.7% | 35.3% | 30.4% | 69.6% | 3.1% | 96.9% |
ELM | SELM<lc(0.352) | lc≤SELM<0.5 | 0.5≤SELM<hc(0.783) | SELM≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 22 | 1 | 5 | 5 | 18 | 26 | 5 | 208 |
 | 95.7% | 4.3% | 50.0% | 50.0% | 40.9% | 59.1% | 2.3% | 97.7% |
KNN | SKNN<lc(0.305) | lc≤SKNN<0.5 | 0.5≤SKNN<hc(0.864) | SKNN≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 23l | 2 | 8 | 1 | 12 | 33 | 7 | 204 |
 | 92.0% | 8.0% | 88.9% | 11.1% | 26.7% | 73.3% | 3.3% | 96.7% |
NB | SNB<lc(0.188) | lc≤SNB<0.5 | 0.5≤SNB<hc(0.869) | SNB≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 32 | 9 | 2 | 5 | 9 | 19 | 7 | 207 |
 | 78.0% | 22.0% | 28.6% | 71.4% | 32.1% | 67.9% | 3.3% | 96.7% |
ADAB | SADA<lc(0.286) | lc≤SADA<0.5 | 0.5≤SADA<hc(0.614) | SADA≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 10 | 0 | 22 | 8 | 3 | 14 | 15 | 218 |
 | 100.0% | 0.0% | 73.3% | 26.7% | 17.6% | 82.4% | 6.4% | 93.6% |
LOG | SLOG<lc(0.317) | lc≤SLOG<0.5 | 0.5≤SLOG<hc(0.820) | SLOG≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 18 | 1 | 13 | 4 | 15 | 27 | 7 | 205 |
 | 94.7% | 5.3% | 76.5% | 23.5% | 35.7% | 64.3% | 3.3% | 96.7% |
LDA | SLDA<lc(0.256) | lc≤SLDA<0.5 | 0.5≤SLDA<hc(0.958) | SLDA≥hc | ||||
 | benign | malignancy | benign | malignancy | benign | malignancy | benign | malignancy |
 | 27 | 2 | 4 | 2 | 13 | 24 | 6 | 212 |
 | 93.1% | 6.9% | 66.7% | 33.3% | 35.1% | 64.9% | 2.8% | 97.2% |
Management | After a 6-month | After 3-month | Â | FNA biopsy | ||||
of thyroid | sonographic | sonographic follow-up | FNA biopsy | or surgical | ||||
nodules | follow-up | or FNA biopsy | Â | treatment |